Orlando, Elena J.
Novartis (Switzerland)
3 papers on CoChatORCID 0009-0004-6448-8874
Most cited papers
- Verified
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
Fraietta, J. A., Lacey, S. F., Orlando, E. J., Pruteanu-Malinici, I., Gohil, M., Lundh, S., Boesteanu, A. C., Wang, Y., O’Connor, R. S., Hwang, W.-T., et al. (2018) · Nature Medicine
CAR-T cell therapy researchChronic Lymphocytic Leukemia Research
Cited by 1,785
- Verified
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine
CAR-T cell therapy researchImmunotherapy and Immune Responses
Cited by 659
- Verified
Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction
Singh, N., Lee, Y. G., Shestova, O., Ravikumar, P., Hayer, K. E., Hong, S. J., Lu, X. M., Pajarillo, R., Agarwal, S., Kuramitsu, S., et al. (2020) · Cancer Discovery
CAR-T cell therapy researchAcute Lymphoblastic Leukemia research
Cited by 295
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free